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This invention pertains to crystals of serum albumin and processes for growing them.
The purpose of the invention is to provide crystals of serum albumin which can be studied
to determine binding sites for drugs. Figure 2 is a photograph showing Form 2 crystals
which grow in the monoclinic space P21 and possesses the following unit cell constraints: a
= 58.9 + 7, b = 88.3 + 7, c = 60.7 + 7, Beta = 101.0 + 2 degrees. One advantage of the
invention is that it will allow rational drug design
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ORIGIN OF THE INVENTIQN
This invention was made by an employee of the United States
Government and may be manufactured and used by or for the
Government for governmental puposes without the payment of any
5 royalties.
FIELD OF THE INVENTION
The present invention is related to the use of albumin in
structural studies related to drug binding and genetic
engineering and, more particularly, to high quality crystal forms
i0 prepared from human, baboon and canine serum albumin which are
suitable for conducting drug and ligand binding experiments.
BACKGROUND OF THE Ib_NT_QN
Serum albumin, a protein of multiple functions and manifold
applications, is one of the most extensively studied proteins in
15 biochemistry. As the most abundant protein in the circulatory
system and with typical blood concentrations of 5 g/!00 ml, serum
albumin contributes 80% to colloid osmotic blood pressure. In
addition, it has now been determined that albumin is chiefly
responsible for the maintenance of blood pH. It is located in
20 every tissue and bodily secretion, with the extracellular protein
comprising 60% of total albumin. In mammals, albumin is
synthesized by the liver and possesses a half-life in circulation
of 19 days. Complete amino acid sequences are known for bovine,
rat, and human serum albumins.
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While the principal function of serum albumin remains
unknown, it is clear that serum albumin contributes to many
transport and regulatory processes. Many studies have focused on
the multi-functional binding properties of serum albumin to
various metals, fatty acids, hormones, and a wide spectrum of
therapeutic drugs. The majority of these binding studies have
involved human serum albumin ("HSA") and many have shown that the
distribution, free concentration, and metabolism of various
pharmaceuticals can be significantly altered as a function of the
magnitude of binding to HSA.
Serum albumin is the principal carrier of fatty acids that
are otherwise insoluble in circulating plasma. But albumin
performs many other functions as well, such as sequestering
oxygen free radicals and inactivating various toxic lipophilic
metabolites such as bilirubin. Although albumin has a broad
affinity for small, negatively charged aromatic compounds, it has
high affinities for fatty acids, hematin, and bilirubin.
Additionally, it forms covalent adducts with pyridoxal phosphate
cysteine, glutathione, and various metals, such as Cu(II), Ni(II)
Hg(II), Ag(II), and Au(I).
It is widely accepted in the pharmaceutical industry that
the overall distribution, metabolism, and efficacy of many drugs
can be altered based on their affinity to serum albumin. In
addition, many promising new drugs are rendered ineffective
because of their unusually high affinity to serum albumin. Some
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studies have suggested that modified serum albumin may be used as
a selective contrast agent for tumor detection and/or therapy.
Other studies have demonstrated that albumin may be used to
deliver toxic compounds for elimination of Mycobacterium
tuberculosis via receptor-mediated drug delivery. Recently,
chimeric albumin molecules such as HSA-CD4 and HSA-Cu,Zn-
superoxide dismutase have been utilized to increase the half-life
and distribution, and reduce the immunogenicity of these
potential protein therapeutics.
In order to study the use of albumin in rational drug
design, it is necessary to understand its structure and the
chemistry of drug/ligand binding. The power of rational drug
design has recently been reviewed by Bugget al., Druas by
DesigD, 92 Scientific American (December, 1993). A requirement
of rational drug design is the production of crystals of the
desired target protein which provide for the determination of the
detailed atomic structure of both the parent protein and its
complex with the pharmaceutical. A tetragonal crystal form of
human serum albumin, described in U.S. Patent No. 4,833,233,
provided means for the first atomic structure determination of
human serum albumin. Consequently, this crystal form has been
utilized to explain a great deal about serum albumin structure
and chemistry particularly in regard to the mode of ligand
binding taught by Carter & Ho, Structure of Serum Albumin, 45
Advances in Protein Chemistry 153 (1994). However, this crystal
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form has the disadvantage of an intrinsic limit on the
diffraction data, namely to 2.9 angstroms and limited stability
under x-irradiation.
S__ARY OF THE IS_ENTION
Thus, it is a purpose of the present invention to overcome
the disadvantage of the prior art and thereby provide high
quality crystals of serum albumin.
In accordance with a preferred embodiment of the invention
human serum albumin crystals are prepared which exhibit x-ray
diffraction resolutions to d-spacings of 2.4 angstroms (_) or
less. In a preferred form, the crystals have a monoclinic space
group P2_, and the following unit cell constants a = 58.9 (7), b
= 88.3 (7), c = 60.7 (7) and Beta = i01 (2) degrees. The
crystals are prepared from recombinant or naturally isolated
serum albumin.
In another preferred embodiment, canine albumin crystals
("CSA") are prepared which exhibit x-ray diffraction resolutions
to d-spacings of 2.2 angstroms or less.
It is, therefore, an object of the present invention to
provide serum albumin crystals for studies directed toward
improving the efficacy, delivery or metabolism of various high
potential pharmaceuticals that are rendered ineffective by serum
albumin.
This and other objects of the present invention will become
apparent from the detailed description to follow.
c : \'45 [\ _meIld Lmr'_ca :re r (bah)
4
5i0
15
2O
25
BRIEF DESCRIPTION OF THE DRAWINGS
There follows a detailed description of the preferred
embodiments of the present invention which are to be taken
together with the accompanying drawings, wherein:
Figure 1 is a photograph showing one of the crystal forms
(Form I) of HSA embodying the present invention.
Figure 2 is a photograph showing another one of the crystal
forms (Form II) of HSA embodying the present invention.
Figure 3 is a photograph showing high quality crystals of
CSA, space group PI.
Figure 4 is a photograph showing high quality crystals of
HSA containing from 3 to iO molar excess of long chain fatty
acid, monoclinic space group C2 (Form III).
DESCRIPTION OF THE PREFERRED EMBODIMGNT
Monoc!inic plate-like crystals of human serum albumin in
accordance with the method of the present invention are grown
from a precipitant solution of polyethylene glycol ("PEG"), and a
buffer, with concentration of reagents and pH being carefully
controlled within prescribed limits. Any of the three basic
techniques generally used for growth of protein crystals, that
is, "hanging-drop" or vapor diffusion, dialysis and batch methods
may be employed. The hanging-drop method is, however, preferred.
Further, either recombinant HSA or naturally isolated HSA may be
used for crystal growth.
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In the hanging drop method a small drop of protein solution
is placed on a cover slip, or glass plate, which is inverted over
a well of solution and sealed. The solution in the well contains
a precipitating agent, which is also present in a lesser amount
in the protein droplet. The function of the precipitating agent
is twofold. First, the solution in the well is initially at a
lower vapor pressure than the protein droplet so that evaporation
progresses at a rate fixed by the difference in the vapor
pressures and the distance by which the vapor, usually water,
must diffuse. Second, the precipitating agent lowers the
solubility of the protein in solution by competing with the
protein for available solvent. Thus, as evaporation from the
protein droplet occurs, the solution becomes supersaturated in
protein. Under the appropriate conditions including pH, protein
concentration and temperature, crystallization of the protein or
macromolecule then occurs.
A stock solution of PEG is prepared by combining 50 weight
percent PEG having a molecular weight on the order of 3350
grams/mole with 50 weight percent water. The precipitant
solution is then prepared by mixing the stock solution with an
appropriate buffer (usually 0.05 molar) to adjust the pH and
starting concentration. Appropriate buffers include sodium
acetate, sodium citrate and Tris (hydroxymethyl) aminomethane-
ma!eate and potassium phosphate. However, monobasic sodium
phosphate (NaHPQ) is the preferred buffer. As a general
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guideline for preparing the precipitant solution, 35 weight
percent of the stock solution is combined with 65% of the
phosphate buffer which has a pH between 4.6 and 8.0. Most
preferably, the buffer solution remains neutral, that is, pH 7.5.
Once the precipitant solution is prepared, additional pH
adjustments may be required to compensate for variations in pH
which can arise from variations in molecular weight and residue
content of PEG. These adjustments are carried out by adding
small amounts of a base such as potassium hydroxide or an acid
such as hydrochloric acid to the precipitant solution. If the
hanging-drop method is employed for crystal growth, the droplet
is preferably formed using i0 microliters (_I) of the precipitant
solution and i0 _i of HSA having a concentration of 90 to 200
mg/ml, preferably 120 mg/ml. The droplet is sealed in a chamber
and equilibrated over a 1 ml reservoir solution of the
precipitant solution. Within ten days to three weeks, crystals
appear and reach sizes of up to 0.7 mm in the largest dimension,
with total dimensions being on the order of 0.7 mm x 0.15 mm x
0.2mm.
HSA crystals appear in two forms. Figure 1 is a photograph
showing the Form I crystals which typically appear before the
more preferred, Form II crystals. The Form I crystals are less
mechanically stable and exhibit poorer diffraction
characteristics. Figure 2 is a photograph showing the Form II
crystals which grow in the monoclinic space group P2 L and
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possesses the following unit cell constants: a = 58.9 (7), b =
88.3 (7), c = 60.7 (7), Beta =!01 (2) degrees.
The quality of protein crystals is determined by the ability
of the crystal to scatter x-rays of wavelengths (typically 1.0 to
1.6 A) suitable to determine the atomic coordinates of the
protein. The measure of the quality is determined as a function
of the highest angle of scatter (the ultimate or intrinsic
resc!uticn) and according to Bragg's Law: nk = 2dsinS, d may be
determined, and represents the resolution of the crystal form in
angstroms. Thus, this measurement is routinely used to judge the
ultimate usefulness of protein crystals. The International Union
of Crystallographers has determined that there are 230 unique
ways in which chemical substances, proteins or otherwise, may
assemble in three-dimensions to form crystals. These are called
the 230 "space groups." The designation of the space group in
addition to the unit cell constants (which define the explicit
size and shape of the cell which repeats within the crystal) is
routinely used to uniquely identify a crystalline substance.
Certain conventions have been established to ensure the proper
identification of crystalline materials and these conventions
have been set forth and documented in the International Tables
for Crystallography, incorporated herein by reference.
High quality crystals of baboon serum albumin ("BbSA") are
prepared under identical conditions to those for human serum
albumin. The crystals grow in the monoclinic space group P2
I
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possess substantially the same unit cell constants as the HSA
crystals. The BbSA forms can be used as substitutes in studies
of human drug/albumin interactions where crystallization of the
complexes are only possible with this species. The principles of
this application has been convincingly demonstrated at the atomic
level by Ho et al., X-ray and primary_ structure of horse serum
albumin (Equus caballus) at 0.27-nm resolutiQm, 215 Eur. J.
Biochem. 205 1993) in the comparison of the ligand binding
properties of horse serum albumin with human serum albumin, and
by Carter and Ho, HLhQ_r_ar. Thus, the precise atomic interactions
between proteln and ligand can only be provided by a
determination of the corresponding crystal structure. Although
most of the important key residues involved in ligand binding by
albumin are conserved among the various species, there can also
exist selective differences in albumin ligand binding chemistry
between species as discussed in C.F. Chignell, 2 CRC Handbook 9f
Biochemistry and Molecular BiQloc__, 554-582 (1976).
Figure 3 is a photograph showing high quality crystals of
CSA. The crystals possess the following unit cell constants: a =
51.7 (7) A, b : 66.6 (7) A, c : 108.1 (9) A, alpha = 90.4 (9),
beta = 107.9 (9), gamma = 93.1 (9) degrees. These crystals were
grown using a hanging-drop method with 56-60% volume/volume (v/v)
saturated ammonium sulphate solution. Appropriate buffers for
preparing CSA crystals include TRIS, cacodylate, citrate
phosphate and potassium phosphate. However, the preferred buffer
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is KHPO 4 at pH 7.5 to 8.0. The droplet was prepared using i0_I
of the precipitant solution and I0_i of CSA having a
concentration of 180 mg/ml, although CSA crystals may be grown
with lower protein concentration. The resulting crystals
exhibited x-ray diffraction resolutions to d-spacings less than
2.2 angstroms, thereby providing a means for high resolution
studies of drug/ligand interaction with albumin. Both
baboon and canine serum albumin are important in drug efficacy,
and delivery, i.e., rational drug design, because they represent
important animal models for human efficacy trials. In
particular, differences in the chemistry of drug binding between
albumins often reflects important differences in their respective
albumins, as taught by Carter & Ho, ___. This difference is
reflected in their primary structures. Thus, an understanding of
these interactions may provide further insight in future studies
of new promising pharmaceuticals in human trials. Similarly
their different chemistries also provide other avenues in genetic
engineering studies and the production of novel albumin based
therapeutics.
To obtain structural information about the protein/drug
interaction to allow rational drug design, it is also necessary
to prepare a crystal of the complex, the complex being the drug
bound to the serum albumin. Crystals of the complex can be
produced using two different methods. In a first method, the
actual complex itself is crystallized using the prescribed
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conditions set forth for the native serum albumin(s), i.e., HSA,
BbSA or CSA. Once crystals of suitable size have grown, x-ray
diffraction data are collected. This process usually involves
_he measurements of many tens of thousands of diffracted x-rays
over a period of one to several days depending on the crystal
form and the resolution of the data required. According to the
method, crystals are bombarded with x-rays. The crystals
diffract the rays, creating a geometrically precise splatter of
spots on photographic film or electronic detectors. The
distribution of atoms within the crystal influences the pattern
of spots Subtraction of the data F_ -= using phases from
the atomic model of the albumin structure produces the electron
density of only the drug molecule• Visualization of the observed
electron density superimposed on the atomic coordinates derived
from the same crystal form provides a determination of key
protein drug interactions that are necessary for rational drug
design. In the normal practice of the invention, this would be
an iterative process involving several cycles of modeling with
each of the new drugs synthesized as a result of the changes
suggested by the crystal structure of the complex. In the second
commonly practiced method, the drugs or ligands may be soaked
into the crystal because of the inherently large aqueous solvent
channels present in protein crystals. (See. e.g,, Carter et al.,
244 Science, 1195-1198 (1989).) The crystalline complex thus
formed follows the same procedure described above to provide the
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genetic engineering studies is that there is no complex formed.
Instead, a crystal of the genetically altered albumin is grown by
the prescribed methods, the x-ray data is collected, the
resulting structure is refined by any of a variety of known
methods, and the desirable or undesirable consequences of the
engineered change is assessed by direct comparison with the
atomic structure of the native molecule.
In another preferred embodiment of the invention, long chain
fatty acids are added to the HSA in ratios. The phrase "long
chain fatty acids" is used to define any of the common saturated
or unsaturated fatty acids such as palmitic, eicon, myristic and
lauric acid. Furthermore, addition of propionic acid and
caprylic acid in trace amounts from less than 0.i to 2 mole fatty
acid/mole HSA may enhance the production of favorable crystal
form (Form II) .
Figure 4 is a photograph showing high quality crystals of
HSA containing from 3 to I0 molar excess of long chain fatty
acid. These crystals produce a new crystal form, Form III,
which, like the BbSA and CSA crystals, also exhibits favorable
diffraction properties as indicated in the table below. As will
be apparent by the examination of Table i, the serum albumin
crystals described herein represent very high quality and can be
reproducibly grown.
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TABLE i
CRYgTAL DATA ON ,'HE _)LY._3RPHS OF SERUM ALBG,NIN
MC;:OC _ ini,: Mcnocl [nio Monet [h_ic (:Ir_ ho _'humbi c Ovt hoFhombic Te.t ,,-agona [ T_c ragona I
Space Group: C2 P2, C2 P2_2,2, P2,2,2 P4,2,2
or P4,2,2
a • :34.0
c = 276.0
10
15
20
25
3O
35
Un!: ?ell
Di_ns :OILS
(,.urn
: its0
L_O 1 u,_nt
COLt _ eIlt :
LI:
Moi_cu les pez"
A s',"_,:a Z l"[C
Di f f :',_c_ion
L_mit_
p I'_3r_e i:l :
(Fo:_ ill}
R e _e l"-_!;I:e_ :
a = 187.2 a - 58. <) a = 126.5 a = 155.0 a . 137.]
b = 3g.0 b = @3.3 b = 3q.] b - _3.0 b . 275.0
C = 96.9 C = 60.7 C = 135.2 C = 122.0 C = 5d.02
B = LOL.g 13 = _3.3
P42_2
a = i_'7.0
b - 81 .0
35% 33% 51% 52% 5q% 54% 78%
118,130 66,492
21,037 23,502
6.£% 4.6%
i L I" 2" 3" i" I
2.4 2.35 2.5 3.7 3.0 3.8
HIA HSA H3A HSA HSA HSA
iFo_ If)
_his work thi,_ ",,,ork (!) (1) _2) (t)
2.q
H3A
[3,41
4O
45
5O
_: total nu._})er of reflect[oLls measured; u: nttrnber of unique reflections
_mez'_: l" I_,_-I_,I/ -l_); ": ba2ed on published prelimina:-/ es_[ma[eJ.
i. R.J. MoClure and B.M. Craven, 239 J. Mo]. 8iq. 845-849 (1974).
2. S.:;. Rao et a!. 25[ J. Biol. Ch_. 3191-3193 (1976).
3. D.C. Carter, et al., 244 _ 1[95-Iiq8 {IWSC)).
4. D.C. Ca:-te_', U.,_. Patent No. 4,813,233.
5. J.X. Ho e_ al., 215 Eu:'. J. Biol-hem. 201-212, {1993).
TABLE I (cont.)
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CRYSTAL DATA ON THE _)L'fMORPHS ")F :gERUM ALB[IMIN
'TzD'_':__ _. _/.q'._m:
He;<a g cI:a _ TV ic [ i_ ic Monet [ _n i C
6O
65
7O
75
8O
85
3Qace .._VOLip : P6, P [
Unit Cel[ a = 96.2 a = 51.7
DLmensLons c : 144.0 b : 66.6
(r.rn) c = [08.1
CL = 90.4 _ = 100.4
: 107.9
y= 93.1
Solvent 43 _. 28%
i:on t e:I% :
n: i23, 203
u: 42,7g0
Rme :'ge : LO .2%
Molecules pe_
A s,/mmeE z"iO 2
Pi [ f ra,:_ ion 2 . 2
Limits:
{A)
Protein:
Re [e UeI_oes :
i
2.7
P2,
a = 5'_.0
b : 86.9
C = 60.5
33%
16,355
8,472
8.3%
I
2.7
ESA CSA BbSA
(1,5} _iS work _is work
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Other co-crystallization complexes have also been formed with
iodinated fatty acid of lauric acid and numerous chemically
diverse ligands, such as bilirubin, hematin and warfarin with
suitable diffraction quality with reflections measured less than
2.8 angstrom resolution.
Although the invention has been described in considerable
detail with respect to preferred embodiments thereof, variations
and modifications will be apparent to those skilled in the art
without departing from the spirit and scope of the invention as
set forth in the claims.
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ABSTRACT OF THE INVENTION
Serum albumin crystal forms have been produced which
exhibit superior x-ray diffraction quality. The crystals are
produced from both recombinant and wild-type human serum albumin,
canine, and baboon serum albumin and allow the performance of
drug-binding studies as well as genetic engineering studies. The
crystals are grown from solutions of polyethylene glycol or
ammonium sulphate within prescribed limits during growth times
from one to several weeks and include the following space groups:
P2_, C2, PI.
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